PMID- 33504740
OWN - NLM
STAT- MEDLINE
DCOM- 20211109
LR  - 20211109
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 44
IP  - 4
DP  - 2021 Apr 1
TI  - Characterization of an Expanded IL-10-Producing-Suppressive T Cell Population 
      Associated with Immune Tolerance.
PG  - 585-589
LID - 10.1248/bpb.b19-01072 [doi]
AB  - An increase in the number of glucocorticoid-induced tumor necrosis factor 
      receptor-family related gene/protein (GITR)(+)CD25(-) (or fork-head box protein 
      3: Foxp3(-)) CD4(+) T cells, after treating a mouse model of arthritis with 
      fingolimod (FTY720), and a pathogenic antigen may play a key role in the 
      establishment of immune tolerance. In this study, we characterized a specific 
      expanded T cell subset in this population. Mice with glucose-6-phosphate 
      isomerase peptide (GPI(325-339))-induced arthritis were treated with FTY720 
      (1 mg/kg, per os) and GPI(325-339) (10 microg/mouse, intravenously) for five days, 
      starting from the onset of symptoms. The expanded GITR(+)CD25(-) (or Foxp3(-)) 
      CD4(+) T cell population and its cytokine production were examined using flow 
      cytometry. Furthermore, time-dependent changes in T-bet and/or early growth 
      response gene 2 (Egr-2) expression in this T cell subset were examined. The 
      density of T cell immunoreceptors with immunoglobulin (Ig) and immunoreceptor 
      tyrosine-based inhibition motif domains (TIGIT)(+)CD39(+) cell subset in the 
      GITR(+)Foxp3(-)CD4(+) T cell population was significantly increased only in the 
      combined treatment group, compared to that in the untreated and single-treatment 
      groups. In the TIGIT(+)CD39(+)GITR(+)Foxp3(-)CD4(+) T cell population, 
      T-bet(+)Egr-2(+)/T-bet(+)Egr-2(-) cell ratio increased in the latter stage of the 
      treatment. Furthermore, this T cell subset, which corresponded to a T helper 1 
      (Th1) response, produced high levels of both interleukin (IL)-10 and interferon 
      (IFN)-gamma. In conclusion, expanded TIGIT(+)CD39(+)GITR(+)Foxp3(-)CD4(+) T cells 
      shifted from an effector Th1 to IL-10-producing-suppressor T cell phenotype, 
      which may promote an immune-tolerant state.
FAU - Yoshida, Yuya
AU  - Yoshida Y
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
FAU - Mikami, Norihisa
AU  - Mikami N
AD  - Department of Experimental Immunology, Immunology Frontier Research Center, Osaka 
      University.
FAU - Nakanishi, Yusuke
AU  - Nakanishi Y
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
FAU - Saimoto, Maya
AU  - Saimoto M
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
FAU - Nagaike, Arata
AU  - Nagaike A
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
FAU - Shimono, Haruka
AU  - Shimono H
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
FAU - Nakano, Shohei
AU  - Nakano S
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
FAU - Tsuji, Takumi
AU  - Tsuji T
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
FAU - Kohno, Takeyuki
AU  - Kohno T
AD  - Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, 
      Setsunan University.
LA  - eng
PT  - Journal Article
DEP - 20210126
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Antigens, CD)
RN  - 0 (Cytokines)
RN  - 0 (Glucocorticoid-Induced TNFR-Related Protein)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (T cell Ig and ITIM domain protein, mouse)
RN  - 0 (Tnfrsf18 protein, mouse)
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 3.6.1.5 (Apyrase)
RN  - EC 3.6.1.5 (CD39 antigen)
RN  - EC 5.3.1.9 (Glucose-6-Phosphate Isomerase)
RN  - G926EC510T (Fingolimod Hydrochloride)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Apyrase/metabolism
MH  - Arthritis/chemically induced
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - Cytokines/metabolism
MH  - Fingolimod Hydrochloride/pharmacology
MH  - Flow Cytometry
MH  - Glucocorticoid-Induced TNFR-Related Protein/metabolism
MH  - Glucose-6-Phosphate Isomerase/pharmacology
MH  - Immune Tolerance/*immunology
MH  - Interleukin-10/*metabolism
MH  - Mice
MH  - Mice, Inbred DBA
MH  - Models, Animal
MH  - Receptors, Immunologic/metabolism
MH  - T-Lymphocyte Subsets/*immunology/*metabolism
MH  - T-Lymphocytes, Regulatory/immunology
OTO - NOTNLM
OT  - T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based 
      inhibition motif domain
OT  - fingolimod
OT  - glucocorticoid-induced tumor necrosis factor receptor-family related gene/protein
OT  - immune tolerance
OT  - interleukin-10
OT  - pathogenic antigen
EDAT- 2021/01/29 06:00
MHDA- 2021/11/10 06:00
CRDT- 2021/01/28 05:34
PHST- 2021/01/29 06:00 [pubmed]
PHST- 2021/11/10 06:00 [medline]
PHST- 2021/01/28 05:34 [entrez]
AID - 10.1248/bpb.b19-01072 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2021 Apr 1;44(4):585-589. doi: 10.1248/bpb.b19-01072. Epub 2021 
      Jan 26.